Leonard Heffner is an Oncology physician affiliated with Emory University. OpenAlex indexes 96 publications with 2,664 citations (h-index 27); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1365 Clifton Rd NE
Atlanta, GA 303221013
Telephone
404-778-1900Registry record last updated 8 Jul 2007.
Clinical trials
- Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Sponsor: Acrotech Biopharma Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20222 payments
- BeiGene USA, Inc.Program year20221 payment
- BeiGene, Ltd.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
60.1%Thalidomide Analog27.4%Revlimid58%Pomalyst42%Part D<11 patientsKinase inhibitor17%Imbruvica100%Part D<11 patients+ 2 more classes in this area
Anti-infectives
21.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor17%Valacyclovir100%Part D≥15 patientsShort-acting sulfonamides4.9%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsNervous system
8.7%Gabapentinoids4.9%Gabapentin100%Part D<11 patientsSSRI3.8%Trazodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Venetoclax ex vivo functional profiling predicts improved progression-free survival
Blood Cancer Journal
2022 - Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life
Biology of Blood and Marrow Transplantation
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Guyton, MD
Emory University
Keith Delman, MD
Emory University
Paolo Raggi, MD
Emory University
Monica Farley, MD
Emory University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”